Phase 2 Depression and Anxiety Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 22 years or older.
• People who have an advanced or end-stage illness (of any kind) where life expectancy is estimated to be at least 12 weeks but no more than 2 years.
• People who have a sufficient understanding of what the study involves and the risks it may carry.
• People who are willing to follow all study procedures and sign the consent form.
• People who are willing to avoid driving or operating machinery for 24 hours after receiving the study drug (LSD).
• People who are willing to complete an official "Emergency Medical Directive" document.
• People whose cancer has spread to the brain or central nervous system may still be eligible, but only if all of the following apply: the brain lesions have been treated and are stable, OR are untreated but have shown no signs of change for at least 4 weeks; no seizures have occurred in the last 4 weeks; if taking anti-seizure medication, the dose has been stable for at least 4 weeks with no expected interactions with the study drug; no cancer spreading through the fluid around the brain or spinal cord; and no ongoing blood-thinning (anticoagulation) treatment.

Who may not be able to join:

• People with a life expectancy of less than 12 weeks.
• People with a known allergy or sensitivity to LSD.
• People who are currently taking prescription psychiatric or mind-affecting medications that could interfere with the study drug, and who are unable or unwilling to stop taking them for a required period before the study.
• People currently taking a strong inhibitor of a liver enzyme called CYP2D6 (confirm with trial site for specific medications).
• People who are pregnant, breastfeeding, or planning to become pregnant during the study.
• People with certain serious physical health conditions, including untreated epilepsy with a history of major (grand-mal) seizures, a history of delirium, severe heart failure, untreated or poorly controlled high blood pressure, chest pain (angina), severe liver disease, severely reduced kidney function, or other conditions the investigators judge to carry too great a risk of side effects.
• People who are unable to follow study procedures due to language barriers, psychological difficulties, dementia, or similar reasons.
• People who have participated in another clinical trial involving an experimental drug within the 30 days before joining, or who are currently in another such trial.
• People with a past or current diagnosis of a psychotic disorder, or who have a parent, sibling, or child with a psychotic disorder.
• People with a past or current diagnosis of bipolar disorder.
• People currently experiencing delirium.
• People with a substance use disorder in the past 2 months (not including nicotine, opioids taken for pain relief, or benzodiazepines taken for anxiety).
• People weighing less than 45 kg.
• People who are experiencing suicidal thoughts with an active intention or plan to act on them, as assessed by the treating investigator.
• People whose cancer has spread to the brain or central nervous system in a way that is unstable or high-risk — for example, where the condition is getting worse, there are signs of increased pressure in the skull, there is uncontrolled swelling, steroid doses are being increased, or where any neurological condition is judged to carry too high a risk.
• People who have had brain-directed surgery or radiation therapy within the 4 weeks before joining the study.

Important: Always verify eligibility with the trial site directly before applying.